Why Vertex Pharmaceuticals Is the Best Biotech Stock to Buy in August
One biotech that has been rapidly gaining traction in treating CF is Vertex Pharmaceuticals (NASDAQ: VRTX) and its drug Trikafta. At the same time, the company's shares have returned 24% year to date. Trikafta is now the locomotive leading Vertex Pharmaceuticals's revenue to record levels.